prymal

Eli Lilly dropped topline results for the TRIUMPH-1 Phase 3 trial yesterday, May 21, 2026. The numbers are hard to ignore. Retatrutide (LY3437943) is a triple hormone receptor agonist. It hits GLP-1, GIP, and glucagon receptors at the same time. That glucagon piece is what makes it different...

Hey everyone 👋 I'm back to log a peptide cycle with a new lab supplying the Australian 🇦🇺 domestic market: @Prymal I'll be sharing my training, diet, compound response and progress here over the next 6-7 weeks My basic demographics: Age: Early 30s Training Experience: Intermediate, with...